Your browser doesn't support javascript.
loading
Anticoagulation and Antiplatelet Agent Resumption Timing following Traumatic Brain Injury.
Jung, In-Ho; Yun, Jung-Ho; Kim, Sung Jin; Chung, Jaewoo; Lee, Sang Koo.
Afiliación
  • Jung IH; Department of Neurosurgery, Dankook University College of Medicine, Cheonan, Korea.
  • Yun JH; Department of Neurosurgery, Dankook University College of Medicine, Cheonan, Korea.
  • Kim SJ; Department of Neurosurgery, Dankook University College of Medicine, Cheonan, Korea.
  • Chung J; Department of Neurosurgery, Dankook University College of Medicine, Cheonan, Korea.
  • Lee SK; Department of Neurosurgery, Dankook University College of Medicine, Cheonan, Korea.
Korean J Neurotrauma ; 19(3): 298-306, 2023 Sep.
Article en En | MEDLINE | ID: mdl-37840609
ABSTRACT
Traumatic brain injury (TBI) is a major global health concern. Due to the increase in TBI incidence and the aging population, an increasing number of patients with TBI are taking antithrombotic agents for their underlying disease. When TBI occurs in patients with these diseases, there is a conflict between the disease, which requires an antithrombotic effect, and the neurosurgeon, who must minimize intracranial hemorrhage. Nevertheless, there are no clear guidelines for the reversal or resumption of antithrombotic agents when TBI occurs in patients taking antithrombotic agents. In this review article, we intend to classify antithrombotic agents and provide information on them. We also share previous studies on the reversal and resumption of antithrombotic agents in patients with TBI to help neurosurgeons in this dilemma.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Korean J Neurotrauma Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Korean J Neurotrauma Año: 2023 Tipo del documento: Article